Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,413.20 4.66 0.03%
S&P 500 1,864.59 -0.26 -0.01%
NASDAQ 4,095.02 -0.50 -0.01%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,512.38 -3.89 -0.03%
TOPIX 1,171.40 -1.97 -0.17%
HANG SENG 22,760.24 64.23 0.28%

BG Medicine to Announce Third Quarter 2012 Earnings Results and Commercial Strategy Update and Host Conference Call on Tuesday,



BG Medicine to Announce Third Quarter 2012 Earnings Results and Commercial
Strategy Update and Host Conference Call on Tuesday, November 13, 2012

WALTHAM, Mass., Nov. 7, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc.
(Nasdaq:BGMD) today announced that the company will host a conference call and
webcast on Tuesday, November 13 at 8:00 a.m. Eastern Time to discuss its third
quarter 2012 financial results and to provide an update on its commercial
strategy. The call and webcast will follow the release of the third quarter
financial results before the market opens.

Conference Call Details

To access the live conference call on November 13 at 8:00 a.m. Eastern Time
via phone, please dial (877) 845-1016 from the United States and Canada or
(708) 290-1155 internationally. Please dial in approximately ten minutes prior
to the start of the call.

To access the live and subsequently archived webcast of the conference call,
go to the company's Investor Relations section of its website at
www.bg-medicine.com. Please connect to the website at least 15 minutes prior
to the call to allow for any software download that may be necessary.

A replay of the call can also be accessed by phone and will be available
approximately one hour following the end of the call through November 15,
2012. The replay may be accessed by dialing (855) 859-2056 within the U.S. and
Canada or (404) 537-3406 from international locations, conference ID
#39743107.

About BG Medicine

BG Medicine, Inc. (Nasdaq:BGMD) is a life sciences company focused on the
development and commercialization of novel cardiovascular diagnostics to
address significant unmet medical needs, improve patient outcomes and contain
healthcare costs. The Company's first commercialized product, the BGM
Galectin-3^® test for use in patients with heart failure, is available in the
United States and Europe. BG Medicine is also developing the CardioSCORE^TM
Test, a blood test designed to identify individuals at high risk for near-term
major cardiovascular events, such as heart attack and stroke. For additional
information about BG Medicine, heart failure and galectin-3 testing, please
visit www.bg-medicine.com and www.galectin-3.com.

The BG Medicine Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=10352

CONTACT: Chuck Abdalian
         EVP & Chief Financial Officer
         (781) 434-0210

BG Medicine Inc. logo
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement